The Meakins-Christie Laboratories is one of the premier centres for pulmonary research in the world and Canada. The Meakins was founded in 1972 by Dr. Peter Macklem. It comprises the largest group of investigators within the Translational Research in Respiratory Diseases Program at the RI-MUHC. Our overall mission is to better understand the pathobiology of respiratory disorders. Our goal is to drive innovations in respiratory disease prevention, diagnosis, and therapy. As a result, our research is focused around five main themes: chronic airways disease, lung injury and infection, neuromuscular dysfunction in respiratory diseases, sleep-disordered breathing, and lung cancer.
In the News
Revising our COVID-19 Testing Strategy
Dr. Dick Menzies calls for a more extensive and ultimately less expensive approach to COVID-19 testing for all Canadians.
Warriors at the MUHC
MUHC staff have taken on new responsibilities to meet the demands brought on by COVID-19.
Using β-glucan to help fight TB Infection
Dr. Nargis Khan and Dr. Eva Kaufmann from the Divangahi lab publish their work in Cell Reports
RAMQ: Remove Financial Barriers to Smoking-Cessation!
Dr Jean Bourbeau of the Meakins-Christie Labs and the RESP Program makes funding request to RAMQ
Asthmatic Primary Students at School
Dr. Larry Lands discusses the low risk to most asthmatic primary students as they return to school.
Upcoming Events
CHEST® Journal Club Webinar May 14
Moderated by Dr. Anne Gonzalez of the RECRU and an Associate member of the Meakins-Christie Laboratories
ATS webinar: Genomics of SARS-CoV-2
ATS webinar April 29 on Genomics of SARS-CoV-2, with Dr. Dara Torgerson as moderator.
Innate Immune Memory
Registration and abstract submission is open for the Conference, organized in part by Dr. Divangahi of the Meakins-Christie Labs